PA8431301A1 - Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion - Google Patents

Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion

Info

Publication number
PA8431301A1
PA8431301A1 PA19978431301A PA8431301A PA8431301A1 PA 8431301 A1 PA8431301 A1 PA 8431301A1 PA 19978431301 A PA19978431301 A PA 19978431301A PA 8431301 A PA8431301 A PA 8431301A PA 8431301 A1 PA8431301 A1 PA 8431301A1
Authority
PA
Panama
Prior art keywords
solvates
salts
compounds
intermediates
preparation
Prior art date
Application number
PA19978431301A
Other languages
English (en)
Spanish (es)
Inventor
Scott E Zook
Raymond Dagnino Jr
Michael E Deason
Steven L Bender
Michael Joseph Melnick
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of PA8431301A1 publication Critical patent/PA8431301A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
PA19978431301A 1995-12-08 1997-05-30 Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion PA8431301A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56976695A 1995-12-08 1995-12-08
PCT/US1996/019328 WO1997020824A1 (en) 1995-12-08 1996-12-05 Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation

Publications (1)

Publication Number Publication Date
PA8431301A1 true PA8431301A1 (es) 2000-05-24

Family

ID=24276764

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19978431301A PA8431301A1 (es) 1995-12-08 1997-05-30 Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion

Country Status (39)

Country Link
US (1) US6153757A (enExample)
EP (2) EP0874830B1 (enExample)
JP (1) JP2000502330A (enExample)
KR (1) KR19990072009A (enExample)
CN (2) CN1542002A (enExample)
AP (2) AP1288A (enExample)
AT (2) ATE234291T1 (enExample)
AU (1) AU725831C (enExample)
BG (1) BG64279B1 (enExample)
BR (1) BR9611929A (enExample)
CA (1) CA2238306A1 (enExample)
CO (1) CO4790150A1 (enExample)
CZ (1) CZ292942B6 (enExample)
DE (2) DE69626684T2 (enExample)
DK (1) DK0874830T3 (enExample)
EA (1) EA003294B1 (enExample)
ES (2) ES2195034T3 (enExample)
GE (1) GEP20012388B (enExample)
GT (2) GT199700015A (enExample)
HR (1) HRP970031A2 (enExample)
HU (1) HUP9902092A3 (enExample)
ID (1) ID17624A (enExample)
IL (6) IL124559A (enExample)
MX (1) MX9804457A (enExample)
MY (1) MY117290A (enExample)
NO (1) NO311360B1 (enExample)
NZ (1) NZ325559A (enExample)
OA (1) OA10794A (enExample)
PA (1) PA8431301A1 (enExample)
PE (1) PE69298A1 (enExample)
PL (1) PL327275A1 (enExample)
PT (1) PT874830E (enExample)
SI (1) SI0874830T1 (enExample)
SK (1) SK73898A3 (enExample)
SV (1) SV1997000008A (enExample)
TR (1) TR199800990T2 (enExample)
TW (1) TW546293B (enExample)
WO (1) WO1997020824A1 (enExample)
YU (1) YU21597A (enExample)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500948B1 (en) 1995-12-08 2002-12-31 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
DE69626684T2 (de) * 1995-12-08 2004-04-29 Agouron Pharmaceuticals, Inc., La Jolla Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
PL331369A1 (en) * 1996-07-22 1999-07-05 Monsanto Co Thiosulphonic metaloprotease inhibitors
US6872742B2 (en) 1996-08-28 2005-03-29 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
EP0927161B1 (en) 1996-08-28 2002-10-16 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
JP3347331B2 (ja) 1996-08-28 2002-11-20 ザ プロクター アンド ギャンブル カンパニー 複素環式メタロプロテアーゼ阻害剤
CA2263932A1 (en) * 1996-08-28 1998-03-05 Yetunde Olabisi Taiwo 1,4-heterocyclic metalloprotease inhibitors
AU727820B2 (en) * 1996-08-28 2000-12-21 Procter & Gamble Company, The 1,3-diheterocyclic metalloprotease inhibitors
BR9712792A (pt) * 1996-08-28 1999-12-14 Procter & Gamble Inibidores de metaloprotease bidentada.
US5977408A (en) * 1996-10-16 1999-11-02 American Cyanamid Company Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
DE69718038D1 (de) * 1996-10-16 2003-01-30 American Cyanamid Co Herstellung und verwendung von ortho-sulfonamido-heteroarylhydroxamsäuren als matrix-metalloproteinase und tace inhibitoren
US6228869B1 (en) 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5962481A (en) 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6174915B1 (en) 1997-03-25 2001-01-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
CA2275478A1 (en) * 1996-12-17 1998-06-25 Kentaro Sato Piperazine compounds as inhibitors of mmp or tnf
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6476027B1 (en) 1997-03-04 2002-11-05 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
ES2209122T3 (es) 1997-03-04 2004-06-16 Pharmacia Corporation Compuestos de acido sulfonil alfa-hidroxi hidroxamico aromatico.
US6087359A (en) * 1997-03-04 2000-07-11 Getman; Daniel P. Thioaryl sulfonamide hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
ES2236893T3 (es) * 1997-03-04 2005-07-16 Pharmacia Corporation Compuestos de acido sulfonamida hidroxamico con anillo amidoaromatico.
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
KR20010005940A (ko) * 1997-04-01 2001-01-15 아구론 파마슈티컬스, 인크. 메탈로프로테이나제 억제제를 포함하는 약제학적 조성물 및 이의 약제학적 용도
WO1998050348A1 (en) * 1997-05-09 1998-11-12 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd ２−スルファモイル安息香酸誘導体
WO1999006340A2 (en) 1997-07-31 1999-02-11 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
JPH11199512A (ja) * 1997-10-24 1999-07-27 Pfizer Prod Inc 変形性関節症および他のｍｍｐ媒介疾患の治療のためのｍｍｐ−１３選択的阻害剤の使用
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6541489B1 (en) 1997-11-14 2003-04-01 G. D. Searle & Company Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
EP1051407A1 (en) * 1998-01-27 2000-11-15 American Cyanamid Company 2,3,4,5-tetrahydro-1h-[1,4]-benzodiazepine-3-hydroxamic acids as matrix metalloproteinase inhibitors
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
SK11692000A3 (sk) 1998-02-04 2001-02-12 Novartis Ag Sulfonylaminoderiváty, ktoré inhibujú metaloproteinázy degradujúce matricu, spôsob ich prípravy a farmaceutická kompozícia, ktorá ich obsahuje
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
AU3982599A (en) 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
WO1999065867A1 (en) * 1998-06-17 1999-12-23 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
DK1357109T3 (da) 1998-06-18 2008-09-08 Hoffmann La Roche Fremgangsmåde til arylalkylsulfid
FR2780402B1 (fr) 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
WO2000009492A1 (en) * 1998-08-12 2000-02-24 Pfizer Products Inc. Tace inhibitors
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
CN1320028A (zh) * 1998-09-30 2001-10-31 宝洁公司 使用磺酰胺治疗脱发的方法
US6288261B1 (en) * 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
EA006294B1 (ru) * 1998-12-23 2005-10-27 Дж.Д.Сирл Энд Ко. Применение комбинации целекоксиба и гемцитабина в комбинированном способе лечебного воздействия при лечении рака поджелудочной железы
US6858598B1 (en) * 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6358980B1 (en) 1999-01-27 2002-03-19 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6544984B1 (en) 1999-01-27 2003-04-08 American Cyanamid Company 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
AR022423A1 (es) * 1999-01-27 2002-09-04 American Cyanamid Co Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
SK11352001A3 (sk) 1999-02-08 2002-09-10 G. D. Searle & Co. Metaloproteázový inhibítor kyselina sulfamátohydroxámová
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
WO2000051993A2 (en) 1999-03-03 2000-09-08 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
SK12452001A3 (sk) 1999-03-03 2002-04-04 The Procter & Gamble Company Zlúčenina vytvárajúca inhibítor metaloproteinázy, farmaceutický prostriedok, spôsob prípravy liečiva a liečivo
AUPP982399A0 (en) * 1999-04-19 1999-05-13 Fujisawa Pharmaceutical Co., Ltd. Mmp inhibitor
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6869951B1 (en) 1999-07-16 2005-03-22 Pharmacia Corporation Method of changing conformation of a matrix metalloproteinase
PE20010659A1 (es) 1999-10-01 2001-06-20 Hoffmann La Roche Derivados de las pirimidin-2,4,6-trionas como inhibidores de metaloproteasas
BR0109469A (pt) 2000-03-17 2003-04-29 Bristol Myers Squibb Co Compostos derivados de b-aminoácidos, composição farmacêutica, método para o tratamento ou prevenção de disfunções inflamatórias, método para o tratamento de condições ou doenças mediadas por mmps, tnf, aggrecanase ou uma combinação destes em mamìferos e uso do composto
EP1263755A2 (en) 2000-03-17 2002-12-11 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
ATE330601T1 (de) * 2000-04-07 2006-07-15 Samsung Electronics Co Ltd Sulfonamide als matrix-metalloproteinase inhibitoren
US6683093B2 (en) 2000-05-12 2004-01-27 Pharmacia Corporation Aromatic sulfone hydroxamic acids and their use as protease inhibitors
US6927216B2 (en) 2000-10-03 2005-08-09 Bristol-Myers Squibb Pharma Company Cyclic sulfonyl compounds as inhibitors of metalloproteases
CA2434044A1 (en) 2001-01-11 2002-07-18 Bristol-Myers Squibb Pharma Company 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha
EP1355901A2 (en) 2001-01-11 2003-10-29 Bristol-Myers Squibb Pharma Company 1,1-DISUBSTITUTED CYCLIC INHIBITORS OF MATRIX METALLOPROTEASE AND TNF-$g(a)
FR2819252A1 (fr) * 2001-01-11 2002-07-12 Servier Lab Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
WO2002074738A2 (en) 2001-03-15 2002-09-26 Bristol-Myers Squibb Company Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage)
US6716845B2 (en) 2001-03-30 2004-04-06 Hoffmann-La Roche Inc. Barbituric acid derivatives
CA2446586A1 (en) 2001-05-11 2002-11-21 Thomas E. Barta Aromatic sulfone hydroxamates and their use as protease inhibitors
MXPA03011095A (es) * 2001-05-29 2005-04-28 Guilford Pharm Inc Metodo para tratar una lesion nerviosa causada por cirugia.
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
JP2003081937A (ja) * 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
CA2464727A1 (en) 2001-11-01 2003-05-08 Wyeth Holdings Corporation Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
WO2003048119A2 (en) * 2001-11-30 2003-06-12 Bristol-Myers Squibb Company Method of producing n-[(2s)-sulfanyl-4-(1,5,5-trimethylhydantoinyl)butanoyl]-l-leucyl-l-tert-leucine n-methylamide and intermediate thereof
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
BR0309671A (pt) 2002-04-25 2005-05-03 Pharmacia Corp ácidos de piperidinil- e piperazinil-sulfonilmetil hidroxâmicos e seu uso como inibidores de protease
AU2003233154A1 (en) * 2002-06-10 2003-12-22 Pfizer Inc. Metabolites of prinomastat and their sythesis
EP2428509A1 (en) * 2002-06-12 2012-03-14 Symphony Evolution, Inc. Human adam-10 inhibitors
BR0312036A (pt) * 2002-06-25 2005-04-05 Pharmacia Corp ácido arilsulfonilhidroxâmico e derivados de amida bem como composição farmacêutica contendo os mesmos e uso dos mesmos
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
DE602004020734D1 (de) * 2003-02-14 2009-06-04 Serono Lab Derivate von piperazine-2-carboxamide
EP1596846A2 (en) * 2003-02-18 2005-11-23 Pfizer Inc. Inhibitors of hepatitis c virus, compositions and treatments using the same
ES2315647T3 (es) 2003-03-24 2009-04-01 Actimis Pharmaceuticals, Inc. Derivados 2-fenoxi y 2-fenilsulfonamida con actividad antagonista de ccr3 para el tratamiento del asma y otros trastornos inflamatorios o inmunologicos.
GT200500139A (es) * 2004-06-08 2005-07-25 Metodo para la preparacion de acidos hidroxamicos
US20100226922A1 (en) * 2006-06-08 2010-09-09 Dorothea Maetzel Specific protease inhibitors and their use in cancer therapy
US8426415B2 (en) 2007-10-16 2013-04-23 Symphony Evolution, Inc. Human ADAM-10 inhibitors
EP2147684A1 (en) * 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2011081884A1 (en) 2009-12-14 2011-07-07 Massachusetts Institute Of Technology Systems and methods related to optical nanosensors including photoluminescent nanostructures
IT1401253B1 (it) 2010-04-23 2013-07-18 Uni Degli Studi Carlo Bo Urbino Uso del sulodexide per la riduzione delle metalloproteinasi di matrice.
KR20140072894A (ko) * 2011-10-04 2014-06-13 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 신규의 세포사멸 유도 화합물
JP2022512584A (ja) 2018-10-04 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 角皮症を処置するためのｅｇｆｒインヒビター
JP7484901B2 (ja) * 2019-04-26 2024-05-16 日産化学株式会社 アリールスルホン酸エステル化合物の製造方法
US20220227792A1 (en) * 2019-06-14 2022-07-21 Loyola University Of Chicago Carborane hydroxamic acid matrix metalloproteinase agents for boron neutron capture therapy

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032639A (en) * 1976-03-22 1977-06-28 American Home Products Corporation 2,3,4,4A-Tetrahydro-1H-pyrazino[1,2-a,]quinoxalin-5(6H)-ones and derivatives thereof for relieving hypertension
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
GB9000846D0 (en) * 1990-01-15 1990-03-14 Beecham Group Plc Novel compounds
GB9022117D0 (en) * 1990-10-11 1990-11-21 Beecham Group Plc Novel compounds
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
DE69108529T2 (de) * 1990-12-03 1995-11-30 Celltech Therapeutics Ltd Peptidylderivate.
CA2102890A1 (en) * 1991-05-28 1992-11-29 Soumya P. Sahoo Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
US5256657A (en) * 1991-08-19 1993-10-26 Sterling Winthrop, Inc. Succinamide derivative matrix-metalloprotease inhibitors
GB9211706D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
GB9211707D0 (en) * 1992-06-03 1992-07-15 Celltech Ltd Peptidyl derivatives
US5376664A (en) * 1992-07-27 1994-12-27 The Du Pont Merck Pharmaceutical Company Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents
EP0671911A4 (en) * 1992-11-25 1996-08-21 Merck & Co Inc CARBOXYPEPTIDYL DERIVATIVES AS AN ANTIDEGENERATIVE ACTIVE SUBSTANCES.
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5552419A (en) * 1993-01-06 1996-09-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9307956D0 (en) * 1993-04-17 1993-06-02 Walls Alan J Hydroxamic acid derivatives
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
ES2105744T3 (es) * 1993-08-05 1997-10-16 Syntex Inc Inhibidores de metaloproteasas matriciales.
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
UA48121C2 (uk) * 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
CA2181709A1 (en) * 1994-01-22 1995-07-27 Raymond Paul Beckett Hydroxamic acid derivatives as metalloproteinase inhibitors
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
DE69510198T2 (de) * 1994-05-28 1999-10-28 British Biotech Pharmaceuticals Ltd., Cowley Succinyl hydroxamsäure-, n-formyl-n-hydroxy-aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease-inhibitoren
NZ288299A (en) * 1994-06-22 1998-06-26 British Biotech Pharm Substituted (hetero)aryl-sulphonylaminomethyl-hydroxamic acid and medicaments
GB9416897D0 (en) * 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (pt) * 1995-04-20 2001-04-30 Pfizer Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
DE69624536T2 (de) * 1995-08-08 2003-06-05 Ono Pharmaceutical Co. Ltd., Osaka Hydroxamsäurederivate verwendbar zur Hemmung von Gelatinase
DE19542189A1 (de) * 1995-11-13 1997-05-15 Hoechst Ag Cyclische N-substituierte alpha-Iminohydroxamsäuren
CZ297550B6 (cs) * 1995-11-13 2007-02-07 Hoechst Aktiengesellschaft Cyklická a heterocyklická N-substituovaná alfa-iminohydroxamová a karboxylová kyselina, zpusob jejíprípravy, lécivo tuto slouceninu obsahující, pouzití této slouceniny pro výrobu léciva a zpusob výroby tohoto léciva
SK282833B6 (sk) * 1995-11-17 2002-12-03 Warner-Lambert Company Sulfónamidové inhibítory matricových metaloproteináz a farmaceutická kompozícia obsahujúca tieto inhibítory
DE69626684T2 (de) * 1995-12-08 2004-04-29 Agouron Pharmaceuticals, Inc., La Jolla Metallproteinasehemmer, diesen enthaltende pharmazeutische zusammensetzung und dessen pharmazeutische verwendung und verfahren zu ihrer herstellung
US5753653A (en) * 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
DE69619865T2 (de) * 1995-12-22 2002-11-07 Warner-Lambert Co., Morris Plains Aromatische keto-säure und ihre derivate als inhibitoren der matrix metalloproteinase
US5837224A (en) * 1996-01-19 1998-11-17 The Regents Of The University Of Michigan Method of inhibiting photoaging of skin
KR100338857B1 (ko) * 1996-01-23 2002-05-30 시오노 요시히코 술폰화 아미노산 유도체 및 이를 함유한메탈로프로테이나제 저해제
IL128189A0 (en) * 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
CA2263932A1 (en) * 1996-08-28 1998-03-05 Yetunde Olabisi Taiwo 1,4-heterocyclic metalloprotease inhibitors
EP0927161B1 (en) * 1996-08-28 2002-10-16 The Procter & Gamble Company Substituted cyclic amine metalloprotease inhibitors
US5929097A (en) * 1996-10-16 1999-07-27 American Cyanamid Company Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
EP1095936A1 (en) 2001-05-02
ES2195034T3 (es) 2003-12-01
DE69633947D1 (de) 2004-12-30
EA199800541A1 (ru) 1998-12-24
HUP9902092A2 (hu) 1999-09-28
KR19990072009A (ko) 1999-09-27
EP0874830B1 (en) 2003-03-12
HUP9902092A3 (en) 2000-12-28
IL143674A0 (en) 2002-04-21
CN1542002A (zh) 2004-11-03
CO4790150A1 (es) 1999-05-31
NO982590D0 (no) 1998-06-05
HRP970031A2 (en) 1998-08-31
CN1207289C (zh) 2005-06-22
WO1997020824A1 (en) 1997-06-12
MX9804457A (es) 1998-09-30
ATE234291T1 (de) 2003-03-15
IL134816A0 (en) 2001-05-20
PT874830E (pt) 2003-06-30
AU725831B2 (en) 2000-10-19
BG102510A (en) 1999-08-31
AP2001002270A0 (en) 2001-09-30
CZ173398A3 (cs) 1998-11-11
BR9611929A (pt) 1999-05-18
MY117290A (en) 2004-06-30
OA10794A (en) 2001-07-05
AP1368A (en) 2005-04-21
NZ325559A (en) 2000-01-28
SI0874830T1 (en) 2003-08-31
NO982590L (no) 1998-08-05
DE69633947T2 (de) 2005-12-01
AP9801284A0 (en) 1998-09-30
DE69626684D1 (de) 2003-04-17
TR199800990T2 (xx) 1998-07-21
AU1409197A (en) 1997-06-27
CA2238306A1 (en) 1997-06-12
IL138027A0 (en) 2001-10-31
IL134816A (en) 2003-02-12
NO311360B1 (no) 2001-11-19
IL138028A0 (en) 2001-10-31
CN1207734A (zh) 1999-02-10
ATE283264T1 (de) 2004-12-15
EP0874830A1 (en) 1998-11-04
EA003294B1 (ru) 2003-04-24
PL327275A1 (en) 1998-12-07
DE69626684T2 (de) 2004-04-29
YU21597A (en) 1999-11-22
ES2233275T3 (es) 2005-06-16
BG64279B1 (bg) 2004-08-31
AU725831C (en) 2002-10-17
GT199700015AA (es) 1998-07-23
AP1288A (en) 2004-07-21
ID17624A (id) 1998-01-15
TW546293B (en) 2003-08-11
CZ292942B6 (cs) 2004-01-14
SK73898A3 (en) 1999-01-11
US6153757A (en) 2000-11-28
GT199700015A (es) 1998-07-23
EP1095936B1 (en) 2004-11-24
JP2000502330A (ja) 2000-02-29
IL124559A (en) 2004-07-25
IL138027A (en) 2004-08-31
DK0874830T3 (da) 2003-04-22
GEP20012388B (en) 2001-03-25
PE69298A1 (es) 1998-11-13
SV1997000008A (es) 1999-02-15
IL124559A0 (en) 1998-12-06

Similar Documents

Publication Publication Date Title
PA8431301A1 (es) Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion
ES2121896T3 (es) Derivados de acido hidroxamico como inhibidores de colagenasa.
AR003453A1 (es) Inhibidores de agregado de plaquetas, su uso en la fabricacion de medicamentos, composicion farmaceutica que los contiene y procedimiento para la preparacion de dichos inhibidores
LU90410I2 (fr) Milnacipran (chlorhydrate)
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
ECSP055636A (es) Acidos tienil-hidroxamicos sustituidos, y su uso para tratar enfermedades asociadas con la actividad enzimatica de la histona desacetilasa
ES2083773T3 (es) Derivados de 1,3-dihidro-2h-imidazo(4,5-b)quinolin-2-ona como inhibidores de fosfodiesterasa.
NO960380L (no) Middel til behandling av neurosykdommer
UY24409A1 (es) Inhibidores de la matriz metaloproteasa
DK0683789T3 (da) N-alkyl-2-substituerede ATP-analoger
DK0457686T3 (da) Hidtil ukendte aminopiperidin-, aminopyrrolidin- og aminoperhydroazepinderivater, fremgangsmåder til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES2143526T3 (es) Derivados de amida que tienen actividad antihipercolesterolemica, su preparacion y sus usos terapeuticos.
HN1998000034A (es) Quinoxalinadionas
ES2093237T3 (es) Derivados de hidrazina farmacologicamente activos y procedimiento para su obtencion.
CO5700776A2 (es) Compuestos utiles para el tratamiento de enfermedades
BR0215017A (pt) Lactamas como antagonistas da taquiquinina
MX9306311A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
AR015446A1 (es) Antagonistas de receptores de vitronectina, composicion farmaceutica que los contiene, procedimiento para su preparacion, su uso para la elaboracion de unmedicamento y compuestos intermediarios
ATE243209T1 (de) Tetrahydro gamma-carboline
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
MX9304424A (es) Bencimidazoles, medicamentos que contienen estos compuestos y procedimiento para su preparacion.
ES2090024T3 (es) Compuestos de cefemo y procedimientos para su preparacion.
ES2123499T3 (es) Metodos y composiciones para tratamiento de infecciones virales.
ES2029879T3 (es) Procedimiento para producir derivados de aminas sustituidas.
AR035685A1 (es) Derivados de isoxazolina, sus prodrogas, composiciones farmaceuticas que comprenden dichos compuestos, procesos para preparar dichas composiciones, uso de dichos compuestos para la fabricacion de medicamentos, uso de dichas composiciones para la fabricacion de medicamentos, procesos para la preparac